Astec LifeSciences Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on July 28, 2025. Further, the company has submitted the Exchange a copy of Scrutinizers report.
ASTEC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Astec LifeSciences held its 31st AGM on July 28, 2025 via video conferencing, chaired by Nadir B. Godrej. Five resolutions were put to vote: adoption of FY25 financial statements, re-appointment of Nadir B. Godrej as director, ratification of cost auditor remuneration, appointment of BNP & Associates as secretarial auditor for 5 years (FY26-FY30), and approval of related party transactions with holding company Godrej Agrovet. Resolutions 1 to 4 passed with requisite majority, but Resolution 5 (related party transactions with Godrej Agrovet for FY26) was rejected, with 54.2% voting against (461,102 shares) versus 45.8% in favour (389,675 shares). The annual report also flags a tough FY25, with total income falling to ₹386.9 crore (from ₹463.8 crore) and a net loss of ₹134.7 crore (versus ₹46.9 crore loss in FY24), driven by price and volume headwinds in key enterprise and CDMO products.
The rejection of the related party transaction resolution with Godrej Agrovet is a notable governance event that could create friction with the 64.75% holding parent and may require renegotiation or shareholder re-engagement. Combined with the deeply negative FY25 results (net margin of -35.3%, return on net worth of -44.6%), the stock faces both governance and fundamental headwinds that may weigh on investor sentiment.